Literature DB >> 10421612

OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

M Cvetkovic1, B Leake, M F Fromm, G R Wilkinson, R B Kim.   

Abstract

Fexofenadine, a nonsedating antihistamine, does not undergo significant metabolic biotransformation. Accordingly, it was hypothesized that uptake and efflux transporters could be importantly involved in the drug's disposition. Utilizing a recombinant vaccinia expression system, members of the organic anion transporting polypeptide family, such as the human organic anion transporting polypeptide (OATP) and rat organic anion transporting polypeptides 1 and 2 (Oatp1 and Oatp2), were found to mediate [(14)C]fexofenadine cellular uptake. On the other hand, the bile acid transporter human sodium taurocholate cotransporting polypeptide (NTCP) and the rat organic cation transporter rOCT1 did not exhibit such activity. P-glycoprotein (P-gp) was identified as a fexofenadine efflux transporter, using the LLC-PK1 cell, a polarized epithelial cell line lacking P-gp, and the derivative cell line (L-MDR1), which overexpresses P-gp. In addition, oral and i.v. administration of [(14)C]fexofenadine to mice lacking mdr1a-encoded P-gp resulted in 5- and 9-fold increases in the drug's plasma and brain levels, respectively, compared with wild-type mice. Also, a number of drug inhibitors of P-gp were found to be effective inhibitors of OATP. Because OATP transporters and P-gp colocalize in organs of importance to drug disposition such as the liver, their activity provides an explanation for the heretofore unknown mechanism(s) responsible for fexofenadine's disposition and suggests potentially similar roles in the disposition of other xenobiotics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421612

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  124 in total

Review 1.  Hepatocellular transport proteins and their role in liver disease.

Authors:  C Stanca; D Jung; P J Meier; G A Kullak-Ublick
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.

Authors:  Eleni Aklillu; Sabina Mugusi; Eliford Ngaimisi; Michael Marcus Hoffmann; Sonja König; Victoria Ziesenitz; Gerd Mikus; Walter Emil Haefeli; Johanna Weiss
Journal:  Eur J Clin Pharmacol       Date:  2011-06-01       Impact factor: 2.953

3.  Interactions of green tea catechins with organic anion-transporting polypeptides.

Authors:  Megan Roth; Barbara N Timmermann; Bruno Hagenbuch
Journal:  Drug Metab Dispos       Date:  2011-01-28       Impact factor: 3.922

Review 4.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Drug-phytochemical interactions.

Authors:  Costas Ioannides
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 6.  OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Authors:  Megan Roth; Amanda Obaidat; Bruno Hagenbuch
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

7.  Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

Authors:  Evan D Kharasch; Alysa Walker; Dale Whittington; Christine Hoffer; Pamela Sheffels Bedynek
Journal:  Drug Alcohol Depend       Date:  2009-02-18       Impact factor: 4.492

8.  Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.

Authors:  Yuansheng Zhao; Zhe-Yi Hu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

9.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Authors:  E D Kharasch; P S Bedynek; A Walker; D Whittington; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

Review 10.  Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution.

Authors:  Thomas Gerloff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.